v3.25.0.1
Consolidated Statements of Earnings - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Net revenues $ 56,334 $ 54,318 $ 58,054
Cost of products sold 16,904 20,415 17,414
Selling, general and administrative 14,752 12,872 15,260
Research and development 12,791 7,675 6,510
Acquired IPR&D and milestones 2,757 778 697
Other operating expense (income), net (7) (179) 56
Total operating costs and expenses 47,197 41,561 39,937
Operating earnings 9,137 12,757 18,117
Interest expense, net 2,160 1,684 2,044
Net foreign exchange loss 21 146 148
Other expense, net 3,240 4,677 2,448
Earnings before income tax expense 3,716 6,250 13,477
Income tax expense (benefit) (570) 1,377 1,632
Net earnings 4,286 4,873 11,845
Net earnings attributable to noncontrolling interest 8 10 9
Net earnings attributable to AbbVie Inc. $ 4,278 $ 4,863 $ 11,836
Per share data      
Basic earnings per share (in dollars per share) $ 2.40 $ 2.73 $ 6.65
Diluted earnings per share (in dollars per share) $ 2.39 $ 2.72 $ 6.63
Weighted-average basic shares outstanding (in shares) 1,769 1,768 1,771
Weighted-average diluted shares outstanding (in shares) 1,773 1,773 1,778